Literature DB >> 19567530

Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors.

Wilhelmina H A de Jong1, Graeme Eisenhofer, Wendy J Post, Frits A J Muskiet, Elisabeth G E de Vries, Ido P Kema.   

Abstract

CONTEXT: Measurements of the 3-O-methylated metabolites of catecholamines [metanephrines (MNs)] in plasma or urine are recommended for diagnosis of pheochromocytoma. It is unclear whether these tests are susceptible to dietary influences.
OBJECTIVE: The aim of the study was to determine the short-term influence of a catecholamine-rich diet on plasma and urinary fractionated MNs. DESIGN, SETTING, AND PARTICIPANTS: We conducted a crossover study in a specialist medical center involving 26 healthy adults.
INTERVENTIONS: Subjects consumed catecholamine-rich nuts and fruits at fixed times on one day (about 35 mumol dopamine and 1 mumol norepinephrine) and catecholamine-poor products on another day. Blood and urine samples were collected at timed intervals before, during, and after experimental and control interventions. MAIN OUTCOME MEASURES: Isotope-dilution mass spectrometry-based measurements of plasma and urinary concentrations of free and deconjugated 3-methoxytyramine (3-MT), normetanephrine (NMN), and MN were made.
RESULTS: The catecholamine-rich diet had substantial effects (up to 3-fold increases) on plasma concentrations and urinary outputs of free and deconjugated 3-MT. Dietary catecholamines had negligible influences on free NMN in plasma and urine, but substantial effects (up to 2-fold increases) on deconjugated NMN in plasma and urine. Concentrations of free and deconjugated MN in plasma and urine remained unaffected.
CONCLUSIONS: Dietary restrictions should be considered to minimize false-positive results for urinary and plasma deconjugated MNs during diagnosis of pheochromocytoma. Similar considerations appear warranted for plasma and urinary free 3-MT, but not for free NMN or MN, indicating advantages of measurements of the free compared to deconjugated metabolites.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19567530     DOI: 10.1210/jc.2009-0303

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

1.  Mass spectrometric quantification of salivary metanephrines-A study in healthy subjects.

Authors:  Thamara E Osinga; Anouk N A van der Horst-Schrivers; Martijn van Faassen; Michiel N Kerstens; Robin P F Dullaart; Karel Pacak; Thera P Links; Ido P Kema
Journal:  Clin Biochem       Date:  2016-02-10       Impact factor: 3.281

Review 2.  Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review.

Authors:  Roland Därr; Matthias Kuhn; Christoph Bode; Stefan R Bornstein; Karel Pacak; Jacques W M Lenders; Graeme Eisenhofer
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

3.  Elevated urinary catecholamines and adrenal haemorrhage mimicking phaeochromocytoma.

Authors:  Simon Wordsworth; Ben Thomas; Neera Agarwal; Kate Hoddell; Steve Davies
Journal:  BMJ Case Rep       Date:  2010-12-29

Review 4.  Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness.

Authors:  Gary L Schwartz
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

5.  Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.

Authors:  Graeme Eisenhofer; Karel Pacak; Thanh-Truc Huynh; Nan Qin; Gennady Bratslavsky; W Marston Linehan; Massimo Mannelli; Peter Friberg; Stefan K Grebe; Henri J Timmers; Stefan R Bornstein; Jacques W M Lenders
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

6.  Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment.

Authors:  A S Davison; B Norman; A M Milan; A T Hughes; M Khedr; J Rovensky; J A Gallagher; L R Ranganath
Journal:  JIMD Rep       Date:  2017-11-17

Review 7.  Pheochromocytomas and Hypertension.

Authors:  Joseph M Pappachan; Nyo Nyo Tun; Ganesan Arunagirinathan; Ravinder Sodi; Fahmy W F Hanna
Journal:  Curr Hypertens Rep       Date:  2018-01-22       Impact factor: 5.369

Review 8.  Screening for pheochromocytomas and paragangliomas.

Authors:  Graeme Eisenhofer
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

9.  Reference intervals for plasma free metanephrines with an age adjustment for normetanephrine for optimized laboratory testing of phaeochromocytoma.

Authors:  Graeme Eisenhofer; Peter Lattke; Maria Herberg; Gabriele Siegert; Nan Qin; Roland Därr; Jana Hoyer; Arno Villringer; Aleksander Prejbisz; Andrzej Januszewicz; Alan Remaley; Victoria Martucci; Karel Pacak; H Alec Ross; Fred C G J Sweep; Jacques W M Lenders
Journal:  Ann Clin Biochem       Date:  2012-10-12       Impact factor: 2.057

10.  Plasma-free vs deconjugated metanephrines for diagnosis of phaeochromocytoma.

Authors:  Christina Pamporaki; Roland Därr; Michael Bursztyn; Stephan Glöckner; Stefan R Bornstein; Jacques W M Lenders; Karel Pacak; Axel Krinner; Graeme Eisenhofer
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04-17       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.